Efficacy, pharmacokinetics and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease - van Hoeve, K; Dreesen, E; Hoffman, I (Therapeutic Drug Monitoring, 2019)
et al.